- Home
- PPSI vs AKTX Comparison
PPSI vs AKTX Comparison
Compare PPSI & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPSI
- AKTX
- Stock Information
- Founded
- PPSI 2008
- AKTX N/A
- Country
- PPSI United States
- AKTX United States
- Employees
- PPSI N/A
- AKTX N/A
- Industry
- PPSI Electrical Products
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- PPSI Industrials
- AKTX Health Care
- Exchange
- PPSI Nasdaq
- AKTX Nasdaq
- Market Cap
- PPSI 34.7M
- AKTX 35.7M
- IPO Year
- PPSI N/A
- AKTX N/A
- Fundamental
- Price
- PPSI $3.74
- AKTX $0.98
- Analyst Decision
- PPSI Strong Buy
- AKTX Strong Buy
- Analyst Count
- PPSI 1
- AKTX 1
- Target Price
- PPSI $12.00
- AKTX $5.00
- AVG Volume (30 Days)
- PPSI 5.0M
- AKTX 39.3K
- Earning Date
- PPSI 08-14-2025
- AKTX 08-13-2025
- Dividend Yield
- PPSI 34.48%
- AKTX N/A
- EPS Growth
- PPSI N/A
- AKTX N/A
- EPS
- PPSI 2.90
- AKTX N/A
- Revenue
- PPSI $28,334,000.00
- AKTX N/A
- Revenue This Year
- PPSI $24.01
- AKTX N/A
- Revenue Next Year
- PPSI $19.25
- AKTX N/A
- P/E Ratio
- PPSI $1.47
- AKTX N/A
- Revenue Growth
- PPSI 105.82
- AKTX N/A
- 52 Week Low
- PPSI $2.25
- AKTX $0.85
- 52 Week High
- PPSI $7.00
- AKTX $4.22
- Technical
- Relative Strength Index (RSI)
- PPSI 73.95
- AKTX 42.13
- Support Level
- PPSI $3.05
- AKTX $0.94
- Resistance Level
- PPSI $3.29
- AKTX $1.05
- Average True Range (ATR)
- PPSI 0.34
- AKTX 0.06
- MACD
- PPSI 0.05
- AKTX 0.00
- Stochastic Oscillator
- PPSI 52.63
- AKTX 31.91
About PPSI Pioneer Power Solutions Inc.
Pioneer Power Solutions Inc designs, manufactures, integrates, services, and sells distributed energy resources, on-site and mobile power generation equipment, and a platform of mobile electric vehicle (EV) charging solutions.. Its principal products and services include custom-engineered electrical transformers, switchgear and engine-generator sets and controls, complemented by a national field-service network to maintain and repair power generation assets.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.